6:32 PM
 | 
Mar 24, 2015
 |  BC Extra  |  Politics & Policy

CMS to emphasize clinical utility of prognostic cancer tests

At Tuesday's meeting of the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) to discuss prognostic tests for cancer, CMS's James Rollins said the agency will rely more heavily on clinical utility, in addition to analytical and clinical validity, when evaluating coverage of molecular pathology tests. Rollins is director of CMS's division of items and devices.

CMS convened the panel to discuss 10 types of molecular pathology tests for the prognosis of adenocarcinoma...

Read the full 348 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >